Discussion
The mechanism of aggravation of preexisting heart failure and death after Remicade infusions is unknown. Because TNF-␣ is increased in the serum, circulating monocytes, tissue macrophages, and myocardiocytes in patients with chronic heart failure (together with other parameters of ventricular failure and/or low cardiac output), it has logically been implicated in the pathophysiology of congestive heart failure. TNF-␣ is known to be the cause of cardiac cachexia. Transgenic mice with overexpression of TNF-␣ develop myocardial inflammation, cardiac hypertrophy, and dilated cardiomyopathy. 1 In sepsis, TNF-␣ is believed to stimulate oxidative stress in the failing heart. 2 The acute hemodynamic effects of TNF-␣ are as follows: reduction in cardiac output, dP/dt, blood pressure, and mean circulatory filling pressure. 3 Although these effects are deemed negative, no correlation was found between TNF-␣, its soluble receptors, and left ventricular end diastolic volume and ejection fraction, or pulmonary wedge pressure. 4 In contradiction to the paradigm of TNF-␣ being harmful, other studies reveal that TNF-␣ has a protective negative inotropic action on the failing heart and stimulates the production of heat shock proteins, which enable cells to survive transient stresses, such as ischemia. 5 Injection of TNF-␣ improves survival of TNF-␣ Ϫ/Ϫ knockout mice infected with encephalomyocarditis virus in a dose-dependent manner by increasing viral clearance. 6 It induces protein synthesis in cardiac myocytes through activation of the P13-kinase-Akt/PKB pathway 7 and promotes remodeling at the border of infarcted myocardial tissues. 8 It induces inducible nitric oxide synthase (iNOS) in macrophages but not in myocytes. Chronic TNF-␣ exposure in congestive heart failure results in translocation of transcriptionally inactive p50 homodimers, which constitute an adaptive response to minimize the inflammatory consequences of TNF-␣ exposure. 9 Anti-TNF-␣ treatment reduces TNF-␣ and IL-1␤ but not MCP-1 and IL-6. 10 Unopposed or overexpressed IL-6 promotes cardiac injury by interrupting both the cytokine autoregulatory network and the viral clearance in the viral myocarditis model. 11 The 7 cases of death in patients with chronic heart failure and our 8th case of sudden death in a patient without heart failure should moderate the enthusiasm of those who promote anti-TNF-␣ treatment for congestive heart failure until the balance between harmful and protective effects of TNF-␣ on the failing heart are fully elucidated.
Whatever the issue, the 10 mg/kg dose of infliximab has the probability of being harmful in patients with class III-IV heart failure and should be avoided for now. 
